Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
Barbara M. McGowan, Jens Meldgaard Bruun, Matt Capehorn, Sue D. Pedersen, Kirsi Hannele Pietiläinen, Hanna Angelene, Maria Quiroga, Anette Varbo, David C.W. Lau
The abstract is not reproduced here because its license does not permit redistribution. Read it at the original source.
Record
- Archive ID
- doi:10.1016/s2213-8587(24)00182-7
- Published
- Jul 29, 2024
- Venue
- The Lancet Diabetes & Endocrinology
- DOI
- 10.1016/s2213-8587(24)00182-7
- PubMed
- 39089293
- Categories
- Diabetes Treatment and Management
- Provenance
- openalex